Lead author: Randall Chestnut, chestnut@uw.edu Three part clinical question: Patients: Patients aged >13 years with survivable, blunt, severe traumatic brain injury (TBI). Intervention: Intraparenchymal intracranial pressure monitoring and protocol-based management to maintain intracranial pressure (ICP) less than 20 mm Hg, compared to protocol-based treatment based on imaging and clinical assessment of ICP. Outcome: The primary outcome was a composite endpoint of 21 measures encompassing survival, level of consciousness, functional ability, memory and cognition, and neuropsychological status, measured at six months. Mortality and Extended Glasgow Outcome Score (E-GOS) measured at six months were additionally specified as primary endpoints. Secondary outcomes were length of intensive care stay and systemic complications
The study: A multi-centre, parallel-group, randomised, controlled superiority trial with blinded outcome assessment.
The study patients: Patients aged >13 years of age with severe blunt TBI, defined as those with a Glasgow Coma Scale (GCS)
≤8 on admission or within 48 hours of injury. Patients with penetrating trauma, clearly unsurvivable injuries, or presenting with a GCS of 3 and fixed, dilated pupils were not included.
Patients were recruited from four Bolivian and two Ecuadorean hospitals. There were 648 patients screened for eligibility with 324 patients ultimately randomised. The main reasons for non-enrolment were difficulties in gaining consent (30%), GCS 3 with fixed, dilated pupils (23%), lack of intensive care beds (19%) and refusal to participate (10%).
Intervention group: Patients (n=157) received an intraparenchymal ICP probe and were managed by a protocol consistent with Brain Trauma Foundation guidelines, targeting an ICP of <20 mm Hg.
Control group: Patients (n=167) were managed by a protocol based on pre-trial standards of care in the participating hospitals. ICP was monitored clinically and by CT head imaging, including routine scans on admission, at 48 hours, and at 5-7 days.
Control group patients were more severely injured than ICPmonitored cases with slightly lower presenting GCS (median 4 vs 5), a larger proportion of focal lesions (39% vs 34%), and higher prevalence of compressed basal cisterns on initial CT (87% vs 83%). There were no other appreciable differences in baseline characteristics between the study groups.
Intracranial pressure monitoring in severe traumatic brain injury
Intracranial pressure monitoring with protocol-based management did not improve outcomes following severe traumatic brain injury compared to treatment based on imaging and clinical assessment.
Level of evidence: 1B -(an individual randomised controlled trial with wide confidence intervals)
Appraised by: G Fuller
The evidence: 
CAT reviews
EBM questions:
Do the methods accurately allow testing of the hypothesis?
Partially. Randomised controlled trials are the gold standard approach for assessing the effects of therapies. This study has methodological strengths secondary to its stratified randomised design, sound allocation concealment, a priori adjusted analysis plan, and blinded outcome assessment. The overall risk of systematic errors from selection bias and information bias is consequently low. However, there are several limitations which could challenge internal validity and interpretation of results, but would not be expected to qualitatively alter the study' s findings.
Firstly, despite claiming to have used intention-to-treat analysis, 8% of patients in each study group were not assessed at six months and were excluded from the analysis. The reasons for the loss to follow-up are not reported and excluded patient characteristics are not compared across study groups.
Although this level of missing data is unlikely to seriously influence conclusions, the potential for attrition bias is illustrated by an extreme worst case scenario. Assuming all missing patients in the control group died, while those from the intervention group survived, this would result in crude estimates for six-month mortality which would have a clinically and statistically significant benefit for ICP monitoring (RR 0.73, 95% CI 0.56-0.95; ARR 12.8%, 95% CI 2.1-23.3; NNT 8, 95% CI 5-49).
Additionally, an ad hoc mean imputation technique was pre-specified in the study protocol for handling missing data in components of the composite primary outcome. This method could introduce unpredictable systematic errors if individual endpoints were not well correlated. As missing data levels were not reported, the potential for such selection bias is uncertain but is unlikely to be of great magnitude. Ideally, a principled statistical method such as multiple imputation should be used to calculate an adjusted effect estimate under plausible assumptions for the missing data mechanisms. 1 Secondly, by necessity it was not possible to blind clinicians to treatment allocation, with the concomitant small risk of performance bias. Thirdly, control group patients had discernibly more severe TBI and analyses were only adjusted for randomisation stratification variables. Resultant errors arising from chance confounding are unlikely but cannot be entirely ruled out.
Finally, the study only had a 40% power to detect a 10% difference in favourable outcome on the E-GOS. Given the global public health burden of TBI, even a small absolute benefit from improved treatment could potentially avoid thousands of deaths each year. There is consequently a large risk of type II error for detection of a clinically meaningful treatment effect.
Do the statistical tests correctly test the results to allow
differentiation of statistically significant result? Partially. The composite primary outcome was calculated for each participant as an average of their percentile scores over all 21 component elements. This has the advantage of measuring many important domains of health affected by TBI, but the disadvantages of assuming each component is of equal importance, and an inability to fully account for cases where individual endpoints change in opposite directions. The primary composite outcome was appropriately analysed using a blocked Wilcoxon test, adjusting for the stratification variables of study centre, TBI severity, and age. However, the mean imputation method used for missing data will result in spuriously narrow confidence intervals.
Proportional odds logistic regression models were developed to examine the remaining primary endpoints. Inclusion of study centre as an independent variable will correct for clustering of outcomes, but potentially important confounding variables were not added. Details on model building are not reported and it must therefore be taken at face value that important assumptions implicit in proportional odds modeling are fulfilled.
Are the conclusions valid in light of the results? Partially.
The authors conclude that ICP monitoring and care focused on maintaining ICP <20 mm Hg was not demonstrably superior to ICP management guided by imaging and clinical assessment. However, the results presented are consistent with either a beneficial or detrimental effect from ICP monitoring, and the risk of a type II error is high. 4. Did any results get omitted and why? No. The trial was centrally registered (NCT01068522) and a protocol was pre-specified. All outcomes defined a priori are fully reported, with no suspicion of selective outcome reporting. 5. Did they suggest areas for further research? No. 6. Did they make any recommendations based on the results and were they appropriate? Yes. The authors tentatively suggest that the role of manipulating monitored ICP in TBI may require reassessment. They reiterate the importance of raised ICP in the pathogenesis of TBI and the importance of intensive management. These conclusions are consistent with the reported results. 7. Is this study relevant to my clinical practice? Partially. Up to 5,000 patients sustain severe TBI annually, with ICP monitoring forming a foundation for intensive care management. Accordingly these results have potentially important implications for clinical practice. However, as the study was conducted in middle income countries, the applicability of results requires close scrutiny. Trial data suggests that fundamental tenets of intensive care were comparable to developed world practice, and management protocols were consistent with international consensus guidelines. Conversely, intraparenchymal ICP probes were used rather than intraventricular probes, which may be more widely utilised in more advanced intensive care units. Additionally specialist neuroscience centres typically interpret findings from multi-modality monitoring (ICP waveform, micro-dialysis, brain tissue oxygenation, electro-corticography) rather than use a fixed ICP cut-off value. The observed absence of effect could also reflect a lack of experience with ICP monitoring rather than inefficacy.
Moreover the studied population may not be characteristic of TBI patients in higher income countries. The median age of participants was 29 and the conspicuous subset of elderly patients present in the developing world was not represented. Additionally, field care is markedly less refined in Latin America. Poor pre-hospital resuscitation could result in a more severely injured head injury population due to increased secondary insults or contrarily, milder cases if patients do not survive to hospital. Despite these uncertainties, the study' s reported mortality rate was not dissimilar to published cohorts of severe TBI patients from the UK. [2] [3] [4] 8. What level of evidence does this study represent? 1B -, an individual randomised controlled trial with wide confidence intervals. 9. What grade of recommendation can I make on this result alone? Use only in research (GRADE). This study represents moderate quality evidence according to GRADE criteria; downgraded from high quality due to the indirectness and imprecision of study results. 5 Taken together with the absence of supporting information on patient preferences, adverse effects, and cost-effectiveness, a recommendation cannot be made advocating severe TBI management based on clinical and imaging assessment of ICP, over the current established model of direct ICP monitoring. Further research has a large potential for reducing uncertainty about the optimum management strategy, and is likely to have a high expected value of information, suggesting that an only-in-research recommendation is appropriate for the study' s control group treatment strategy. 10. What grade of recommendation can I make when this study is considered along with other available evidence? Weak (GRADE). A current Cochrane review highlights the complete absence of randomised, controlled trial evidence supporting direct ICP monitoring. 6 A more recent systematic review has described the available body of observational evidence, which is of very low quality, highly heterogeneous, and demonstrates conflicting results. 7 Due to the very high risk of confounding by indication, imprecise and discordant results, and paucity of costeffectiveness estimates, only a weak recommendation in favour of ICP monitoring is justified. 11. Should I change my practice because of these results? No.
Given the concerns regarding type II errors and lack of applicability, the study' s results can only be considered as hypothesis-generating. Further large randomised trials are required to delineate the role of ICP monitoring in advanced intensive care settings, and provide precise effect estimates. 12. Should I audit my current practice? No. This study does not indicate specific audit.
